{
    "id": "3418f3da-20d5-a53b-e063-6394a90a00fb",
    "indications": "Diltiazem hydrochloride tablets are indicated for the management of chronic stable angina and angina due to coronary artery spasm.",
    "contraindications": "Exertional Angina Pectoris Due to Atherosclerotic Coronary Artery Disease or Angina Pectoris at Rest Due to Coronary Artery Spasm:Dosage must be adjusted to each patient’s needs. Starting with 30 mg four times daily, before meals and at bedtime, dosage should be increased gradually (given in divided doses three or four times daily) at 1- to 2-day intervals until optimum response is obtained. Although individual patients may respond to any dosage level, the average optimum dosage range appears to be 180 mg/day to 360 mg/day. There are no available data concerning dosage requirements in patients with impaired renal or hepatic function. If the drug must be used in such patients, titration should be carried out with particular caution.\n\n \n                  \n                     Concomitant Use with Other Cardiovascular Agents\n                  \n                  \n                     \n                        Sublingual NTGmay be taken as required to abort acute anginal attacks during diltiazem hydrochloride therapy.\n \n  \n                     \n                        Prophylactic Nitrate Therapy.Diltiazem hydrochloride may be safely coadministered with short- and long-acting nitrates, but there have been no controlled studies to evaluate the antianginal effectiveness of this combination.\n \n  \n                     \n                        Beta-blockers.(See\n  \n   WARNINGSand\n  \n   PRECAUTIONS.)\n \n  \n                  \n                  30 mg – Diltiazem Hydrochloride tablets may be swallowed whole, crushed, or chewed. Do not split Diltiazem Hydrochloride tablets.\n                  60 mg, 90 mg, and 120 mg – Diltiazem Hydrochloride tablets may be swallowed whole, crushed, or chewed.",
    "warningsAndPrecautions": "Diltiazem hydrochloride tablets, USP 30 mg are supplied in bottles of 30 (NDC 50228-481-30), 100 (NDC 50228-481-01), 500 (NDC 50228-481-05), and 1000 (NDC 50228-481-10). Each white to off white, round shaped, film coated tablet is debossed with “481” on one side and plain on other side.\n                  Diltiazem hydrochloride tablets, USP 60 mg are functional scored tablets supplied in bottles of 30 (NDC 50228-482-30), 100 (NDC 50228-482-01), 500 (NDC 50228-482-05), and 1000 (NDC 50228-482-10). Each white to off white, round shaped, film coated tablet debossed with “482” on one side and score on other side.\n                  Diltiazem hydrochloride tablets, USP 90 mg are functional scored tablets supplied in bottles of 30 (NDC 50228-483-30), 100 (NDC 50228-483-01), 500 (NDC 50228-483-05), and 1000 (NDC 50228-483-10). Each white to off white, oval shaped, film coated tablet debossed with “483” on one side and score on other side.\n                  Diltiazem hydrochloride tablets, USP 120 mg are functional scored tablets supplied in bottles of 30 (NDC 50228-484-30), 100 (NDC 50228-484-01), and 500 (NDC 50228-484-05). Each white to off white, capsule shaped, film coated tablet debossed with “484” on one side and score on other side.\n                  Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Avoid excessive humidity.\n                  \n                  \n                     Manufactured by:\n                       ScieGen Pharmaceuticals Inc \n    Hauppauge, NY 11788 \n    USA\n\n \n                  \n                  Rev. 11/2022",
    "adverseReactions": "Diltiazem hydrochloride tablets are contraindicated in:\n                  \n                     Patients with sick sinus syndrome except in the presence of a functioning ventricular pacemaker\n                     Patients with second- or third-degree AV block except in the presence of a functioning ventricular pacemaker\n                     Patients with hypotension (less than 90 mm Hg systolic)\n                     Patients who have demonstrated hypersensitivity to the drug\n                     Patients with acute myocardial infarction and pulmonary congestion documented by x-ray on admission",
    "ingredients": [
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE, UNSPECIFIED",
            "code": "9XZ8H6N6OH"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "DILTIAZEM HYDROCHLORIDE",
            "code": "OLH94387TE"
        }
    ],
    "organization": "Coupler LLC",
    "name": "Diltiazem Hydrochloride",
    "effectiveTime": "20250501"
}